William A. Gray, MD, FACC, FSCAI

Calcium Corner

Two-Year Results of IMPERIAL: First-Ever Randomized Study of Eluvia and Zilver PTX in Femoropopliteal Artery Lesions

01/01/2020

William A. Gray , MD, FACC, FSCAI;

The Eluvia stent utilizes a drug-polymer combination that provides a sustained release of paclitaxel over one year.

The Eluvia stent utilizes a...

01/01/2020

Cath Lab Digest

Clinical Trial Update

Two-Year Results of IMPERIAL: First-Ever Randomized Study of Eluvia and Zilver PTX in Femoropopliteal Artery Lesions

12/09/2019

William A. Gray , MD, FACC, FSCAI;

Vascular Disease Management talks with IMPERIAL trial co-principal investigator William A. Gray, MD, FACC, FSCAI, System Chief, Division of Cardiovascular Disease; President, Lankenau Heart Institute, Main Line Health, Wynnewood, Pennsylvania.

Vascular Disease Management...

12/09/2019

Vascular Disease Management

Interview

DISRUPT PAD III Trial Summary

07/19/2021

Christopher J. White , DO, MD;

William A. Gray , MD, FACC, FSCAI;

A brief trial summary and interviews with William A. Gray, MD, and Christopher J. White, MD, regarding the DISRUPT PAD trial.

A brief trial summary and...

07/19/2021

Vascular Disease Management

Education

Online Training for Carotid Stenting Professionals

09/05/2008

William A. Gray , MD, FACC, FSCAI;

This online Carotid Education and Stenting Course was developed with four key physician consultants — an interventional cardiologist, a neurosurgeon, an interventional radiologist and a vascular surgeon.

This online Carotid Education...

09/05/2008

Vascular Disease Management

ISET 2023

Charles Tegtmeyer Annual Lecture: The Past, Present and Future of Carotid Stenting

01/27/2023

William A. Gray , MD, FACC, FSCAI;

Watch as Interventional Cardiologist William A. Gray, MD, FACC, FSCAI from Main Line Health in Wynnewood, Pennsylvania, delivers the Charles Tegtmeyer Annual Lecture on "The Past, Present and Future of Carotid Stenting" at ISET 2023.

Watch as Interventional...

01/27/2023

Vascular Disease Management

ISET 2023

Intermediate-Term (24-Month) Results of the TRANSCEND Study: Comparing a Next-Generation Paclitaxel Drug-Coated Balloon (SurVeil DCB) to IN.PACT Admiral DCB in the Treatment of Femoropopliteal Artery Disease

01/17/2023

Kenneth Rosenfield , MD, MHCDS;

Amanda Wright Harvey ;

Peter A. Schneider , MD, FACS;

Marianne Brodmann , MD;

William A. Gray , MD, FACC, FSCAI;

In this session from Tuesday afternoon, Peter A. Schneider, MD, Marianne Brodmann, MD, William Gray, MD, and Kenneth Rosenfield, MD reported 24-month results from the TRANSCEND study, which compared the SurVeil drug-coated balloon (DCB) to...

In this session from Tuesday...

01/17/2023

Vascular Disease Management

Vascular Brachytherapy and the Strontium90 Vascular Brachytherapy System

08/01/2008

Mark Reisman , MD;

William A. Gray , MD, FACC, FSCAI;

Vascular brachytherapy, the delivery of a single dose of a radioactive isotope directly inside the target area of the coronary artery after balloon angioplasty, is the only clinically proven therapy and is the standard of care for patients...

Vascular brachytherapy, the...

08/01/2008

Journal of Invasive Cardiology

Meeting Exclusive

Long-term Safety of Stellarex DCB Across Two ILLUMENATE RCTs: 5-Year Results from a Patient-Level Meta-Analysis

01/24/2022

William A. Gray , MD, FACC, FSCAI;

In a late-breaking session at ISET 2022, William A. Gray, MD, presented the 5-year results from a patient-level meta-analysis of long-term safety of the Stellarex drug-coated balloon.

In a late-breaking session at...

01/24/2022

Vascular Disease Management

Measuring DES Efficacy

06/19/2008

William A. Gray , MD, FACC, FSCAI;

As a physician, what do you consider the most clinically significant measure or measures of efficacy in drug-eluting stent (DES) clinical trials, and why? In patients undergoing intervention, TLR (target lesion revascularization) is the most...

As a physician, what do you...

06/19/2008

Cath Lab Digest

Letters to the Editor

Next Steps to Collecting More Data for Peripheral Vascular Patients: A Continued Discussion Regarding Rigorous Scientific Data

02/05/2014

Jihad A. Mustapha , MD, FACC, FSCAI;

William A. Gray , MD, FACC, FSCAI;

Gary M. Ansel , MD, FACC;

George L. Adams , MD, MHS, MBA, FACC, FSCAI;

Future well-designed and executed randomized control trials that track clinically relevant outcomes, including the cost of the endovascular treatments and long-term outcomes, will enable physicians to determine the optimal therapies for...

Future well-designed and...

02/05/2014

Vascular Disease Management